Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 14/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 13/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 13/20 | 0.45 |
| ▸ | PTGIR | P43119 | 6/20 | 0.43 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839535 | 0.99 | PTGIR (0.44) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| Hydrochloric Acid SCHEMBL5839689 | 0.83 | PTGIR (0.49) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL5839518 | 0.80 | PTGIR (0.46) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL5838826 | 0.75 | SLC6A3 (0.35) | — | |
| SCHEMBL27425615 | 0.73 | KMT2A (0.41) | — | |
| SCHEMBL5838181 | 0.73 | PDK1 (0.42) | — | |
| SCHEMBL7092587 | 0.71 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL5838596 | 0.71 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL5838592 | 0.70 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL5838491 | 0.69 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CPTGIRGPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | BLEY KEITH ROGER (US) | 2003-12-11 | — | — | US | disclosed |
| US-6472536-B1 | SUCH AS 2-(4-(4-CYCLOPENTYLOXYBENZYL)PHENYL)AMINO-IMIDAZOLINE; ANTINOCICEPTIVE AGENTS; IP RECEPTOR ANTAGONISTS; TREATING INFLAMMATORY PAIN | SYNTEX (U.S.A.) LLC | 2002-10-29 | — | — | US | disclosed |
| US-6184242-B1 | 2-(substituted-phenyl)amino-imidazoline derivatives | SYNTEX USA (LLC) | 2001-02-06 | — | — | US | disclosed |
| EP-0902018-A2 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | LTB4R2, LTB4R, ALOX5 | ADRA2A 223/4885ADRA2B 256/4885ADRA2C 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.